Distinguished Speakers Seminar Series
Pre-clinical Evaluation of Targeted Therapies for Pediatric Cancer
When: Nov. 21st, 2024 1:00 pm - 2:00 pm
Seminar Series Details:
About Carol Bult, Ph.D., (The Jackson Lab)
Professor, Knowlton Family Chair, The Jackson Laboratory, Bar Harbor, Maine
Principal Investigator, Mouse Genome Informatics (MGI) Consortium
Deputy Director of the Cancer Center
Scientific Director of the Patient Derived Xenograft (PDX) and Cancer Avatar program
About this Class
The Research to Accelerate Cures and Equity (RACE) for Children Act of 2017 requires companies developing targeted cancer drugs for adults to evaluate those drugs for applicability to pediatric cancer. The NCI-funded Pediatric Preclinical In Vivo Testing (PIVOT) consortium collaborates with industry partners to perform rigorous preclinical testing of novel targeted agents using in vivo models of common pediatric cancers. As pediatric cancer is rare, assembling sufficient numbers of patients for clinical trials is challenging. It highlights the importance of effective preclinical testing for identifying promising agents and agents with low potential for improving treatment options for children with cancer.
Join information
- Alternative Meeting Information:
- Meeting number:
- 2309 763 3797
- Password:
- GmUAeeZ@236
- Join by video system
-
Dial 23097633797@cbiit.webex.comYou can also dial 173.243.2.68 and enter your meeting number.
- Join by phone
-
1-650-479-3207 Call-in number (US/Canada)Access code: 2309 763 3797